Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center
We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), i...
Gespeichert in:
| Veröffentlicht in: | Chemotherapy (Basel) 1999-09, Vol.45 (5), p.325-334 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 334 |
|---|---|
| container_issue | 5 |
| container_start_page | 325 |
| container_title | Chemotherapy (Basel) |
| container_volume | 45 |
| creator | Jacobson, Kalen Rolston, Kenneth Elting, Linda LeBlanc, Barbara Whimbey, Estella Ho, Dah Hsi |
| description | We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients. |
| doi_str_mv | 10.1159/000007223 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_7223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70022942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-b0314e91a14c4ebcecd08b8c76016eb898b1f87c63f5aae43a2c87c7c95008003</originalsourceid><addsrcrecordid>eNptkM1Lw0AQxRdRbK0evHqQKCJ4iO5Xk92jhlqVoofqOWy2k7I1aeJuUuh_74aWKuJchtn3Y_bNQ-iU4FtChvIOdxVTyvZQn3BKQhlLvo_6_lWGjAzjHjpybuFHFjFyiHoE85hJivvoZdo6DXVjMlOYZh1MW7sCUxRqqSFQZbWcB2OryvAV5qoxKwgelPayCVQTqCDpMBsksGzAHqODXBUOTrZ9gD4eR-_JUzh5Gz8n95NQcy6aMMOMcJBEEa45ZBr0DItM6DjCJIJMSJGRXMQ6YvlQKeBMUe3HWMshxsKfMEDXm721rb5acE1aGn9D5xmq1qUxxpRKTj14-QdcVK1dem-pz4pGQuDIQzcbSNvKOQt5WltTKrtOCU67dNNdup493y5ssxJmv8hNnB642gLKaVXk1udj3A8nSSRFZ-xsg30qOwe707efXPwrJk-jTk_rWc6-AS9Bk0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223268806</pqid></control><display><type>article</type><title>Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center</title><source>MEDLINE</source><source>Karger Journals</source><creator>Jacobson, Kalen ; Rolston, Kenneth ; Elting, Linda ; LeBlanc, Barbara ; Whimbey, Estella ; Ho, Dah Hsi</creator><creatorcontrib>Jacobson, Kalen ; Rolston, Kenneth ; Elting, Linda ; LeBlanc, Barbara ; Whimbey, Estella ; Ho, Dah Hsi</creatorcontrib><description>We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.</description><identifier>ISSN: 0009-3157</identifier><identifier>EISSN: 1421-9794</identifier><identifier>DOI: 10.1159/000007223</identifier><identifier>PMID: 10473920</identifier><identifier>CODEN: CHTHBK</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial Infections - microbiology ; Biological and medical sciences ; Cephalosporins - pharmacology ; Drug Resistance, Microbial ; Gram-Negative Bacteria - classification ; Gram-Negative Bacteria - drug effects ; Gram-Negative Bacteria - isolation & purification ; Humans ; Medical sciences ; Microbial Sensitivity Tests ; Microbiology ; Neoplasms - complications ; Neutropenia - complications ; Penicillanic Acid - analogs & derivatives ; Penicillanic Acid - pharmacology ; Pharmacology. Drug treatments ; Piperacillin - pharmacology ; Thienamycins - pharmacology</subject><ispartof>Chemotherapy (Basel), 1999-09, Vol.45 (5), p.325-334</ispartof><rights>1999 S. Karger AG, Basel</rights><rights>1999 INIST-CNRS</rights><rights>Copyright (c) 1999 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-b0314e91a14c4ebcecd08b8c76016eb898b1f87c63f5aae43a2c87c7c95008003</citedby><cites>FETCH-LOGICAL-c448t-b0314e91a14c4ebcecd08b8c76016eb898b1f87c63f5aae43a2c87c7c95008003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1916982$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10473920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacobson, Kalen</creatorcontrib><creatorcontrib>Rolston, Kenneth</creatorcontrib><creatorcontrib>Elting, Linda</creatorcontrib><creatorcontrib>LeBlanc, Barbara</creatorcontrib><creatorcontrib>Whimbey, Estella</creatorcontrib><creatorcontrib>Ho, Dah Hsi</creatorcontrib><title>Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center</title><title>Chemotherapy (Basel)</title><addtitle>Chemotherapy</addtitle><description>We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial Infections - microbiology</subject><subject>Biological and medical sciences</subject><subject>Cephalosporins - pharmacology</subject><subject>Drug Resistance, Microbial</subject><subject>Gram-Negative Bacteria - classification</subject><subject>Gram-Negative Bacteria - drug effects</subject><subject>Gram-Negative Bacteria - isolation & purification</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbiology</subject><subject>Neoplasms - complications</subject><subject>Neutropenia - complications</subject><subject>Penicillanic Acid - analogs & derivatives</subject><subject>Penicillanic Acid - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperacillin - pharmacology</subject><subject>Thienamycins - pharmacology</subject><issn>0009-3157</issn><issn>1421-9794</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkM1Lw0AQxRdRbK0evHqQKCJ4iO5Xk92jhlqVoofqOWy2k7I1aeJuUuh_74aWKuJchtn3Y_bNQ-iU4FtChvIOdxVTyvZQn3BKQhlLvo_6_lWGjAzjHjpybuFHFjFyiHoE85hJivvoZdo6DXVjMlOYZh1MW7sCUxRqqSFQZbWcB2OryvAV5qoxKwgelPayCVQTqCDpMBsksGzAHqODXBUOTrZ9gD4eR-_JUzh5Gz8n95NQcy6aMMOMcJBEEa45ZBr0DItM6DjCJIJMSJGRXMQ6YvlQKeBMUe3HWMshxsKfMEDXm721rb5acE1aGn9D5xmq1qUxxpRKTj14-QdcVK1dem-pz4pGQuDIQzcbSNvKOQt5WltTKrtOCU67dNNdup493y5ssxJmv8hNnB642gLKaVXk1udj3A8nSSRFZ-xsg30qOwe707efXPwrJk-jTk_rWc6-AS9Bk0w</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>Jacobson, Kalen</creator><creator>Rolston, Kenneth</creator><creator>Elting, Linda</creator><creator>LeBlanc, Barbara</creator><creator>Whimbey, Estella</creator><creator>Ho, Dah Hsi</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>19990901</creationdate><title>Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center</title><author>Jacobson, Kalen ; Rolston, Kenneth ; Elting, Linda ; LeBlanc, Barbara ; Whimbey, Estella ; Ho, Dah Hsi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-b0314e91a14c4ebcecd08b8c76016eb898b1f87c63f5aae43a2c87c7c95008003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial Infections - microbiology</topic><topic>Biological and medical sciences</topic><topic>Cephalosporins - pharmacology</topic><topic>Drug Resistance, Microbial</topic><topic>Gram-Negative Bacteria - classification</topic><topic>Gram-Negative Bacteria - drug effects</topic><topic>Gram-Negative Bacteria - isolation & purification</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbiology</topic><topic>Neoplasms - complications</topic><topic>Neutropenia - complications</topic><topic>Penicillanic Acid - analogs & derivatives</topic><topic>Penicillanic Acid - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperacillin - pharmacology</topic><topic>Thienamycins - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacobson, Kalen</creatorcontrib><creatorcontrib>Rolston, Kenneth</creatorcontrib><creatorcontrib>Elting, Linda</creatorcontrib><creatorcontrib>LeBlanc, Barbara</creatorcontrib><creatorcontrib>Whimbey, Estella</creatorcontrib><creatorcontrib>Ho, Dah Hsi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Chemotherapy (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacobson, Kalen</au><au>Rolston, Kenneth</au><au>Elting, Linda</au><au>LeBlanc, Barbara</au><au>Whimbey, Estella</au><au>Ho, Dah Hsi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center</atitle><jtitle>Chemotherapy (Basel)</jtitle><addtitle>Chemotherapy</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>45</volume><issue>5</issue><spage>325</spage><epage>334</epage><pages>325-334</pages><issn>0009-3157</issn><eissn>1421-9794</eissn><coden>CHTHBK</coden><abstract>We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>10473920</pmid><doi>10.1159/000007223</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-3157 |
| ispartof | Chemotherapy (Basel), 1999-09, Vol.45 (5), p.325-334 |
| issn | 0009-3157 1421-9794 |
| language | eng |
| recordid | cdi_karger_primary_7223 |
| source | MEDLINE; Karger Journals |
| subjects | Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial Infections - microbiology Biological and medical sciences Cephalosporins - pharmacology Drug Resistance, Microbial Gram-Negative Bacteria - classification Gram-Negative Bacteria - drug effects Gram-Negative Bacteria - isolation & purification Humans Medical sciences Microbial Sensitivity Tests Microbiology Neoplasms - complications Neutropenia - complications Penicillanic Acid - analogs & derivatives Penicillanic Acid - pharmacology Pharmacology. Drug treatments Piperacillin - pharmacology Thienamycins - pharmacology |
| title | Susceptibility Surveillance among Gram-Negative Bacilli at a Cancer Center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A13%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Susceptibility%20Surveillance%20among%20Gram-Negative%20Bacilli%20at%20a%20Cancer%20Center&rft.jtitle=Chemotherapy%20(Basel)&rft.au=Jacobson,%20Kalen&rft.date=1999-09-01&rft.volume=45&rft.issue=5&rft.spage=325&rft.epage=334&rft.pages=325-334&rft.issn=0009-3157&rft.eissn=1421-9794&rft.coden=CHTHBK&rft_id=info:doi/10.1159/000007223&rft_dat=%3Cproquest_karge%3E70022942%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223268806&rft_id=info:pmid/10473920&rfr_iscdi=true |